Dr. Felip on Immunotherapy Alone or in Combination in Lung Cancer

Enriqueta Felip, MD
Published: Tuesday, Sep 24, 2019



Enriqueta Felip, MD, medical oncologist, Vall d'Hebron University Hospital in Barcelona, Spain, discusses immunotherapy alone versus immunotherapy plus chemotherapy in patients with lung cancer.

In Europe, the standard of care for patients with lung cancer with PD-L1 >50% is immunotherapy alone, explains Felip. Patients must fulfill the inclusion criteria, which includes not having EGFR- and ALK-positive tumors.

However, the majority of patients have PD-L1 <50%, making them better candidates for immunotherapy plus chemotherapy, says Felip. Immunotherapy plus chemotherapy is the standard of care for the majority of patients with lung cancer, but physicians need to know the clinical and molecular characteristics of these patients to determine who will benefit most from either treatment, Felip concludes.
SELECTED
LANGUAGE


Enriqueta Felip, MD, medical oncologist, Vall d'Hebron University Hospital in Barcelona, Spain, discusses immunotherapy alone versus immunotherapy plus chemotherapy in patients with lung cancer.

In Europe, the standard of care for patients with lung cancer with PD-L1 >50% is immunotherapy alone, explains Felip. Patients must fulfill the inclusion criteria, which includes not having EGFR- and ALK-positive tumors.

However, the majority of patients have PD-L1 <50%, making them better candidates for immunotherapy plus chemotherapy, says Felip. Immunotherapy plus chemotherapy is the standard of care for the majority of patients with lung cancer, but physicians need to know the clinical and molecular characteristics of these patients to determine who will benefit most from either treatment, Felip concludes.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x